A Study of GENEVAX-HIV, a Possible Vaccine
Phase 1
Completed
- Conditions
- HIV InfectionsHIV Seronegativity
- Registration Number
- NCT00002232
- Lead Sponsor
- Wyeth-Lederle Vaccines
- Brief Summary
The purpose of this study is to see if it is safe to give GENEVAX-HIV, a potential HIV vaccine, to HIV-negative volunteers. The study also compares the effects of GENEVAX-HIV injected into the muscle to the effects of the drug when injected into the skin.
- Detailed Description
Volunteers receive either intradermal or intramuscular injections of GENEVAX-HIV; humoral and cellular responses are assessed accordingly.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Walter Reed Army Institute of Research
🇺🇸Washington, District of Columbia, United States